WellMedr's materials state that possible GLP-1 effects can include nausea, vomiting, diarrhea, constipation, decreased appetite, headache, and fatigue. The materials also state that clinicians may begin with a lower dose and adjust over time to support tolerability, and that severe or persistent symptoms should be reported to the treating provider.
WellMedr's required safety notice discloses that GLP-1 medications may carry risks including thyroid C-cell tumors and medullary thyroid carcinoma. Patients are instructed to seek immediate care for neck swelling, hoarseness, trouble swallowing, or shortness of breath. These symptoms require prompt medical evaluation - not a support email. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are generally not considered candidates for GLP-1 therapy. Medical appropriateness varies by patient; the clinician intake process is described as evaluating this eligibility.
This article does not characterize WellMedr's program or its medications as safe, side-effect free, gentle for all patients, or clinically appropriate for any specific reader. Safety disclosures, possible side effects, and medical appropriateness are determined through clinician review. Patients should consult a licensed healthcare professional before starting, adjusting, or discontinuing any GLP-1 medication program.
